Real-World Effectiveness, Safety, and Tolerability of Adjuvant CDK4/6 Inhibitor Therapy
Background: This study evaluates the real-world effectiveness, safety, and tolerability of adjuvant abemaciclib or ribociclib combined with a non-steroidal aromatase inhibitor (NSAI) in high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer in Western In...